SeekingAlpha · Jul 15, 2026
Turn Therapeutics: Small Market Cap, Huge Potential
Turn Therapeutics offers high risk-reward potential, hinging entirely on its late-stage asset GX-03 for Eczema and Onychomycosis. Click for more on TTRX stock.
TT
NASDAQ · TTRX
Turn Therapeutics Inc.
Healthcare · Biotechnology
$9.86
Down-$0.68 (-6.45%)
Updated Aug 14, 2026, 9:50 AM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 96.14M
- P/E ratio
- 0
- Dividend yield
- 0.00%
- 52-week range
- $2.57 – $26.50
- Volume
- 1
- Avg. volume
- 595.4K
Price performance
TTRX price history
1M range · 22 trading sessions · Daily adjusted prices
TTRX closed at $9.85 after 22 trading sessions, up 9.03% for the selected period.
- Last close
- $9.85
- Period change
- +9.03%
- Period low
- $7.43
- Period high
- $10.54
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $9.845 | $9.845 | $9.845 | $9.845 | 1 |
| Aug 13, 2026 | $10.32 | $10.74 | $9.80 | $9.86 | 64.52K |
| Aug 12, 2026 | $10.30 | $10.9529 | $10.25 | $10.54 | 68.77K |
| Aug 11, 2026 | $9.75 | $10.5699 | $9.63 | $10.22 | 66.41K |
| Aug 10, 2026 | $10.50 | $10.50 | $9.57 | $9.60 | 19.78K |
| Aug 7, 2026 | $9.78 | $10.59 | $9.58 | $10.41 | 88.76K |
| Aug 6, 2026 | $9.14 | $9.89 | $8.6162 | $9.61 | 100.57K |
| Aug 5, 2026 | $9.52 | $9.99 | $8.97 | $9.43 | 32.89K |
| Aug 4, 2026 | $8.85 | $9.825 | $8.58 | $9.52 | 44.88K |
| Aug 3, 2026 | $8.51 | $8.84 | $8.43 | $8.84 | 12.4K |
| Jul 31, 2026 | $8.36 | $8.595 | $8.07 | $8.36 | 46.76K |
| Jul 30, 2026 | $7.48 | $8.35 | $7.40 | $8.25 | 86.85K |
| Jul 29, 2026 | $7.65 | $7.765 | $7.165 | $7.43 | 72.84K |
| Jul 28, 2026 | $7.81 | $8.18 | $7.65 | $7.70 | 46.17K |
| Jul 27, 2026 | $8.59 | $8.6322 | $7.715 | $7.78 | 74.56K |
| Jul 24, 2026 | $9.66 | $9.81 | $8.50 | $8.54 | 99.77K |
| Jul 23, 2026 | $9.64 | $9.90 | $9.47 | $9.48 | 67.05K |
| Jul 22, 2026 | $10.11 | $10.25 | $9.60 | $9.62 | 50.7K |
| Jul 21, 2026 | $10.02 | $10.48 | $9.49 | $10.18 | 171.73K |
| Jul 20, 2026 | $9.34 | $10.20 | $9.34 | $10.05 | 196.01K |
| Jul 17, 2026 | $8.88 | $9.45 | $8.51 | $9.12 | 104.61K |
| Jul 16, 2026 | $9.535 | $9.8092 | $8.91 | $9.03 | 88.92K |
Latest TTRX news
The latest Smart Investors Daily articles mentioning TTRX.
Stock researchCompany · Overview
TTRX research
Overview
Company profile and research snapshot.
Company profile
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 24, 2026 | D. Boral Capital | Buy | — |
| Jan 20, 2026 | D. Boral Capital | Buy | — |
| Dec 29, 2025 | D. Boral Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Jul 7, 2026
Why Is Turn Therapeutics Stock Trading Higher Today?
Turn Therapeutics expanded its GX-03 Phase 2 trial after interim data supported efficacy across a broader atopic dermatitis population.
Benzinga · Jul 7, 2026
Turn Therapeutics Completes Comprehensive Interim Analysis Of Ongoing Adaptive Phase 2 Clinical Trial Evaluating GX-03 For Treatment Of Atopic Dermatitis
Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as
Benzinga · Jul 6, 2026
Turn Therapeutics To Present Data On Its Interim Analysis Of Its Current Adaptive Phase 2 Study Of GX-03 In Atopic Dermatitis
Turn Therapeutics, Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast on Tuesday, July 7,
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
